Among 7 analysts covering MiMedx Group (NASDAQ:MDXG), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. MiMedx Group had 9 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, April 19 by Lake Street. The rating was maintained by First Analysis with “Overweight” on Wednesday, January 20. On Monday, December 12 the stock rating was initiated by UBS with “Sell”. The stock of MiMedx Group Inc (NASDAQ:MDXG) earned “Buy” rating by Aegis Capital on Tuesday, November 8. The stock of MiMedx Group Inc (NASDAQ:MDXG) has “Buy” rating given on Wednesday, October 14 by Needham. The company was downgraded on Wednesday, July 29 by Needham. Canaccord Genuity maintained MiMedx Group Inc (NASDAQ:MDXG) on Friday, December 18 with “Buy” rating. The stock of MiMedx Group Inc (NASDAQ:MDXG) earned “Strong Buy” rating by Needham on Monday, November 16. As per Friday, October 30, the company rating was upgraded by Northland Capital. See MiMedx Group Inc (NASDAQ:MDXG) latest ratings:
12/12/2016 Broker: UBS Rating: Sell New Target: $9 Initiate
08/11/2016 Broker: Aegis Capital Rating: Buy Initiate
The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is a huge mover today! About 2.70 million shares traded or 2231.67% up from the average. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 46.12% since August 25, 2016 and is downtrending. It has underperformed by 54.88% the S&P500.The move comes after 5 months positive chart setup for the $24.34M company. It was reported on Apr, 3 by Barchart.com. We have $5.80 PT which if reached, will make NASDAQ:CYCC worth $2.19 million more.
Investors sentiment is 0 in 2016 Q4. Its the same as in 2016Q3. It is the same, as 0 investors sold Cyclacel Pharmaceuticals Inc shares while 1 reduced holdings. only 0 funds opened positions while 0 raised stakes. 13,286 shares or 2.21% less from 13,586 shares in 2016Q3 were reported. Baker Bros Ltd Partnership reported 0% stake. Tower Rech Limited Liability Co (Trc) owns 33 shares.
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The company has market cap of $24.34 million. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. It currently has negative earnings. The Company’s family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065.
Investors sentiment increased to 1.22 in Q4 2016. Its up 0.07, from 1.15 in 2016Q3. It increased, as 16 investors sold MiMedx Group Inc shares while 47 reduced holdings. 23 funds opened positions while 54 raised stakes. 54.88 million shares or 0.33% more from 54.70 million shares in 2016Q3 were reported. Merriman Wealth Limited Liability Company invested in 1.39% or 572,644 shares. Murphy Capital Inc stated it has 0.03% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG). Blackrock Fund accumulated 7.80 million shares. Barclays Public Limited Company holds 0% or 16,582 shares in its portfolio. Wildcat Capital Mgmt Ltd Liability holds 1.08M shares. Prudential Fin accumulated 171,230 shares. First Trust Advsrs Lp has invested 0% in MiMedx Group Inc (NASDAQ:MDXG). State Of Tennessee Treasury Department invested in 79,166 shares. Natixis reported 10,982 shares. Creative Planning holds 0% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG) for 1,408 shares. Raymond James Fincl Advsrs invested 0% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG). Sei Invs reported 926 shares. Deutsche Bank & Trust Ag accumulated 82,480 shares or 0% of the stock. Amalgamated Bankshares accumulated 0.01% or 13,520 shares. Great West Life Assurance Can invested in 0% or 196,582 shares.
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The company has market cap of $1.07 billion. The Firm operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. It has a 91.28 P/E ratio. The Company’s biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix.
Since March 6, 2017, it had 0 insider purchases, and 2 sales for $641,928 activity. Taylor William Charles sold 26,000 shares worth $212,792. 50,486 MiMedx Group Inc (NASDAQ:MDXG) shares with value of $429,136 were sold by KOOB CHARLES E.
About 115,522 shares traded. MiMedx Group Inc (NASDAQ:MDXG) has risen 32.55% since August 25, 2016 and is uptrending. It has outperformed by 23.79% the S&P500.
